-
Dec 10, 2024 | 
outsourcing-pharma.com | Larissa Warneck-Silvestrin |Liza Laws |Isabel Cameron |Almac Group
Pharma company, AbbVie, reports that its D1/D5 partial agonist, tavapadon, has met the primary and secondary endpoints in a pivotal Phase 3 trial. The trial, called TEMPO-2, evaluated the investigational drug as a flexible-dose monotherapy for individuals with early Parkinson’s disease. Tavapadon is the first partial agonist of the dopamine receptors D1/D5, helping to activate them in people with Parkinson’s disease. About suffer from Parkinson’s disease, with the number expected to double by 2050.
-
Dec 10, 2024 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Liza Laws |Almac Group
Shortly after acquiring a manufacturing site in Wisconsin, Eli Lilly intends to expand it to boost its production of injectable products, including diabetes and obesity drugs Mounjaro and Zepbound. Eli Lilly has announced a $3bn expansion of its manufacturing facility in Kenosha County, Wisconsin, in the context of the growing demand for its diabetes and obesity drugs, as well as future medicines across other therapeutic areas.
-
Dec 10, 2024 | 
northernirelandchamber.com | Almac Group
The Almac Group has launched a new sustainability initiative for Primary 6 and 7 children across Northern Ireland. The “Climate-Action-in-a-Box” programme is a five lesson, hands-on resource specifically designed to engage and educate children with a solution-based programme exploring climate change and action. Almac is investing £30,000 in the programme and plans to reach 2,000 children across 40 primary schools over the next three years.
-
Dec 5, 2024 | 
outsourcing-pharma.com | Jonathan Smith |Liza Laws |Almac Group
The pharma arm of Mitsubishi Chemical Group has launched a collaboration with US-based Dewpoint Therapeutics to co-develop a preclinical-stage treatment for the neurological condition amyotrophic lateral sclerosis (ALS). As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in addition to undisclosed “near-term” developmental milestone payments, with the whole deal worth up to $480m.
-
Dec 5, 2024 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Liza Laws |Almac Group
Investment in radiopharmaceuticals is ramping up as big pharma shows a growing appetite for this promising drug modality. Radiopharmaceuticals see radioactive isotopes being delivered into a target, typically a cancer cell, to kill it. While they have existed for decades, interest in this drug modality was originally limited due to the elevated risk of side effects associated with this approach.
-
Dec 3, 2024 | 
outsourcing-pharma.com | Liza Laws |Almac Group
The pharmaceutical business unit of the German giant Körber has snapped up the compatriot label and leaflet supplier Wilhelm Bähren GmbH & Co as the pharmaceutical packaging market is set to double in the coming decade. Körber’s pharmaceutical segment offers products to store and transport drug products, including folding boxes, sustainable packaging and secure boxes to deter tampering, counterfeiting, and unsupervised use by children.
-
Dec 3, 2024 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Almac Group
Swiss oncology specialist Novocure has announced positive topline results from the PANOVA-3 phase 3 clinical trial, which evaluated the use of tumor treating fields (TTFields) therapy in combination with the chemotherapy drugs gemcitabine and nab-paclitaxel. The trial met its primary endpoint of a significant improvement in median overall survival in patients with unresectable, locally advanced pancreatic adenocarcinoma.
-
Nov 28, 2024 | 
outsourcing-pharma.com | Almac Group
Spray drying involves converting pharmaceutical liquid solutions into tiny droplets that are rapidly dried with hot gases such as nitrogen. This turns medicinal products into fine powders that can be easier to take as inhalable or oral formulations, especially for compounds that are hard to dissolve in water.
-
Nov 28, 2024 | 
outsourcing-pharma.com | Almac Group
The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational small molecule drug, Neflamapimod, for the treatment of frontotemporal dementia. The FDA’s decision is on based promising results from the company’s Phase 1 and 2 studies. Frontotemporal dementia is a rare neurological condition affecting approximately 50,000 to 60,000 people in the US and about 110,000 in the EU.
-
Nov 27, 2024 | 
outsourcing-pharma.com | Jess Spiring |Almac Group
We’re thrilled to announce that we have migrated Confectionery News to a new platform. Our expert coverage of the chocolate, candy and cocoa sector won’t change, but we’ve tweaked the look and feel of the site to bring you improved navigation, more content-rich articles, enhanced search capabilities and a better browsing experience. We’ve been working hard behind the scenes to ensure it’s a seamless transfer for our readers.
